Vogenx Set to Join the Russell 2000(R), Russell 3000(R), and Russell Microcap(R) Indexes
Key Highlights
- ➤Vogenx (VOGX) set to join Russell 2000, Russell 3000, and Russell Microcap indexes
- ➤Index membership expected after markets close December 11, 2026, subject to final determination
- ➤Russell inclusion comes four months after Vogenx’s IPO
- ➤Mizagliflozin advances in Phase 2b EMERGE study for post-bariatric hypoglycemia
Expert Statements
James Green, Chief Executive Officer of Vogenx
“Joining the Russell indexes just four months after our IPO is an important milestone for Vogenx”
James Green, Chief Executive Officer of Vogenx
“Index inclusion broadens our visibility with institutional and index-based investors at a time when we are advancing mizagliflozin in our Phase 2b EMERGE study for post-bariatric hypoglycemia, a serious condition with no FDA-approved treatment.”
James Green, Chief Executive Officer of Vogenx
“We look forward to engaging with a wider investor base as we work toward key clinical milestones.”
RALEIGH, NC / ACCESS Newswire / November 19, 2026 / Vogenx, Inc. (Nasdaq:VOGX), a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced that it is set to join the broad-market Russell 2000®, Russell 3000® Index, and Russell Microcap® Index as part of FTSE Russell's December 2026 semi-annual reconstitution of the Russell US Indexes. Membership will take effect after the U.S. equity markets close on Friday, December 11, 2026, according to the preliminary list of additions FTSE Russell published on November 13, 2026.
Russell index membership is determined by objective, rules-based criteria, chiefly total market capitalization as of the rank day. The December 2026 reconstitution is the first December reconstitution of the Russell US Indexes in more than three decades, following FTSE Russell's move to a semi-annual (June and December) schedule this year.
Get started
Create a free account to read the full story.
